GlassScriptPhysician profile
Fraida Streiter
NPI 1154099539
$6,708.61
in general payments reported to CMS, 2019-2025
15 companies · $1,442 in 2025
The $1,442 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.08 · 2022: $1,154 · 2023: $1,939 · 2024: $2,080 · 2025: $1,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,461.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,880.45 | 2022-2025 | Trintellix |
| Lundbeck LLC | $1,334.55 | 2022-2025 | Rexulti, Abilify Maintena |
| Neos Therapeutics, LP | $1,021.18 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| Tris Pharma INC | $840.25 | 2021-2025 | Dyanavel Xr, Onyda Xr |
| Axsome Therapeutics, INC. | $670.06 | 2022-2025 | Auvelity |
| Corium, LLC | $228.06 | 2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $197.94 | 2022-2025 | Caplyta |
| Almatica Pharma LLC | $175.81 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Janssen Pharmaceuticals, INC | $162.80 | 2023-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $57.09 | 2022-2024 | Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $57.04 | 2024 | Fanapt |
| Alkermes, INC. | $24.92 | 2022 | |
| Alfasigma USA, INC. | $21.46 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $21.09 | 2024 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $15.91 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fraida Streiter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.